Cite
Creelan BC, Gabrilovich DI, Gray JE, et al. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017;10:4239-4250doi: 10.2147/OTT.S136992.
Creelan, B. C., Gabrilovich, D. I., Gray, J. E., Williams, C. C., Tanvetyanon, T., Haura, E. B., Weber, J. S., Gibney, G. T., Markowitz, J., Proksch, J. W., Reisman, S. A., McKee, M. D., Chin, M. P., Meyer, C. J., & Antonia, S. J. (2017). Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. OncoTargets and therapy, 104239-4250. https://doi.org/10.2147/OTT.S136992
Creelan, Ben C, et al. "Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors." OncoTargets and therapy vol. 10 (2017): 4239-4250. doi: https://doi.org/10.2147/OTT.S136992
Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017. PMID: 28919776; PMCID: PMC5587199.
Copy
Download .nbib